Skip to main content
. 2021 May 20;41(5):BSR20203145. doi: 10.1042/BSR20203145

Table 2. Characteristics of include studies.

Authors/Year Year Study period Age mean (range) Cases Type Markers Methods TAM distribution NOS score
Stroma High expression Counts
Chen, X.J. et al. [15] 2019 2011–2013 NR 38 SCC CD163 IHC _ _ 7
Chen, et al. [16] 2019 2012.1–2013.12 NR 72 NR CD163 IHC _ 6
Yan, et al. [17] 2018 2011.1–2013.12 NR 41 SCC CD163 IHC 7
Liu, et al. [18] 2018 2013.6–2016.6 50 (35–82) 65 SCC CD68 IHC _ 7
Wang, et al. [19] 2018 2014.12–2017.6 NR (24–81) 100 SCC, AC and ASC CD68, CD163 IHC _ _ 6
Li, et al. [20] 2017 2012.1–2012.12 NR 109 SCC CD163 IHC _ 6
Chen, et al. [21] 2017 2011–2013 NR 45 SCC CD68, CD163 IHC 7
Shen, et al. [22] 2016 2013–2015 NR (28–71) 60 SCC,AC, ASC and NC CD163 IHC _ 7
Petrillo, et al. [23] 2015 2009.3–2011.12 55 (22–79) 84 SCC, AC CD68, CD163 IHC _ _ 6
Ding, et al. [24] 2014 2015.1–2017.12 NR 55 SCC CD68 IHC _ 7
Liu, et al. [25] 2005 1996.1–1998.12 39 (25–68) 59 SCC, AC CD68 IHC _ 6

Abbreviations: AC, cervical adenocarcinoma; ASC, adenosquamous carcinoma of cervix; FCM, flow cytometry; IHC, immunohistochemistry; NC, neuroendocrine carcinoma; NR, not reported; SCC, cervical squamous cell carcinoma.